Passage Bio Inc. (PASG)
0.59
-0.05 (-7.80%)
At close: Jan 14, 2025, 3:59 PM
0.62
5.07%
After-hours Jan 14, 2025, 07:53 PM EST
undefined% (undefined)
| Bid | 0.58 |
| Market Cap | 36.45M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.17 |
| PE Ratio (ttm) | -0.5 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.65 |
| Volume | 409,441 |
| Avg. Volume (20D) | 765,818 |
| Open | 0.63 |
| Previous Close | 0.64 |
| Day's Range | 0.58 - 0.63 |
| 52-Week Range | 0.45 - 1.79 |
| Beta | undefined |
About PASG
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 28, 2020
Employees 58
Stock Exchange NASDAQ
Ticker Symbol PASG
Website https://www.passagebio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for PASG stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 1086.24% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
+11.4%
Passage Bio shares are trading higher after the co...
Unlock content with
Pro Subscription
